ABBOTT INDIA | JUBILANT LIFE SCIENCES | ABBOTT INDIA/ JUBILANT LIFE SCIENCES |
|||
---|---|---|---|---|---|
P/E (TTM) | x | 46.7 | 16.5 | 282.7% | View Chart |
P/BV | x | 15.2 | 3.1 | 494.5% | View Chart |
Dividend Yield | % | 0.5 | 0.5 | 93.3% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ABBOTT INDIA Mar-19 |
JUBILANT LIFE SCIENCES Mar-19 |
ABBOTT INDIA/ JUBILANT LIFE SCIENCES |
5-Yr Chart Click to enlarge
|
||
High | Rs | 8,834 | 898 | 983.8% | |
Low | Rs | 5,458 | 618 | 883.8% | |
Sales per share (Unadj.) | Rs | 1,731.1 | 572.0 | 302.6% | |
Earnings per share (Unadj.) | Rs | 211.9 | 36.2 | 585.0% | |
Cash flow per share (Unadj.) | Rs | 219.9 | 59.5 | 369.5% | |
Dividends per share (Unadj.) | Rs | 65.00 | 4.50 | 1,444.4% | |
Dividend yield (eoy) | % | 0.9 | 0.6 | 153.2% | |
Book value per share (Unadj.) | Rs | 945.2 | 301.9 | 313.1% | |
Shares outstanding (eoy) | m | 21.25 | 159.28 | 13.3% | |
Bonus/Rights/Conversions | - | - | - | ||
Price / Sales ratio | x | 4.1 | 1.3 | 311.6% | |
Avg P/E ratio | x | 33.7 | 20.9 | 161.2% | |
P/CF ratio (eoy) | x | 32.5 | 12.7 | 255.2% | |
Price / Book Value ratio | x | 7.6 | 2.5 | 301.2% | |
Dividend payout | % | 30.7 | 12.4 | 246.9% | |
Avg Mkt Cap | Rs m | 151,848 | 120,694 | 125.8% | |
No. of employees | `000 | 3.5 | 2.4 | 145.8% | |
Total wages/salary | Rs m | 4,356 | 19,260 | 22.6% | |
Avg. sales/employee | Rs Th | 10,555.5 | 38,120.6 | 27.7% | |
Avg. wages/employee | Rs Th | 1,249.9 | 8,058.4 | 15.5% | |
Avg. net profit/employee | Rs Th | 1,292.2 | 2,414.3 | 53.5% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 36,786 | 91,108 | 40.4% | |
Other income | Rs m | 1,133 | 357 | 317.0% | |
Total revenues | Rs m | 37,919 | 91,466 | 41.5% | |
Gross profit | Rs m | 6,047 | 17,390 | 34.8% | |
Depreciation | Rs m | 169 | 3,709 | 4.6% | |
Interest | Rs m | 23 | 2,198 | 1.0% | |
Profit before tax | Rs m | 6,989 | 11,840 | 59.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -2,802 | 0.0% | |
Tax | Rs m | 2,485 | 3,268 | 76.0% | |
Profit after tax | Rs m | 4,503 | 5,770 | 78.0% | |
Gross profit margin | % | 16.4 | 19.1 | 86.1% | |
Effective tax rate | % | 35.6 | 27.6 | 128.8% | |
Net profit margin | % | 12.2 | 6.3 | 193.3% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 27,610 | 45,848 | 60.2% | |
Current liabilities | Rs m | 8,569 | 20,897 | 41.0% | |
Net working cap to sales | % | 51.8 | 27.4 | 189.0% | |
Current ratio | x | 3.2 | 2.2 | 146.9% | |
Inventory Days | Days | 60 | 57 | 106.0% | |
Debtors Days | Days | 27 | 51 | 53.8% | |
Net fixed assets | Rs m | 1,057 | 65,498 | 1.6% | |
Share capital | Rs m | 213 | 159 | 133.4% | |
"Free" reserves | Rs m | 19,873 | 47,930 | 41.5% | |
Net worth | Rs m | 20,086 | 48,089 | 41.8% | |
Long term debt | Rs m | 0 | 42,429 | 0.0% | |
Total assets | Rs m | 29,409 | 114,685 | 25.6% | |
Interest coverage | x | 311.6 | 6.4 | 4,878.9% | |
Debt to equity ratio | x | 0 | 0.9 | 0.0% | |
Sales to assets ratio | x | 1.3 | 0.8 | 157.5% | |
Return on assets | % | 15.4 | 6.9 | 221.5% | |
Return on equity | % | 22.4 | 12.0 | 186.9% | |
Return on capital | % | 34.9 | 12.4 | 281.2% | |
Exports to sales | % | 0 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | NA | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 369 | 12,422 | 3.0% | |
Fx outflow | Rs m | 4,918 | 17,227 | 28.6% | |
Net fx | Rs m | -4,549 | -4,805 | 94.7% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 4,991 | 11,215 | 44.5% | |
From Investments | Rs m | -2,570 | -10,118 | 25.4% | |
From Financial Activity | Rs m | -1,428 | 6,574 | -21.7% | |
Net Cashflow | Rs m | 993 | 7,612 | 13.0% |
Indian Promoters | % | 0.0 | 45.6 | - | |
Foreign collaborators | % | 75.0 | 3.5 | 2,142.9% | |
Indian inst/Mut Fund | % | 7.9 | 8.7 | 90.8% | |
FIIs | % | 0.1 | 21.2 | 0.5% | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 17.1 | 21.1 | 81.0% | |
Shareholders | 18,270 | 23,815 | 76.7% | ||
Pledged promoter(s) holding | % | 0.0 | 15.9 | - |
Compare ABBOTT INDIA With: NEULAND LABS DR. REDDYS LAB GSK PHARMA ALEMBIC PROCTER & GAMBLE HEALTH
Compare ABBOTT INDIA With: ACTAVIS (US) ADCOCK INGRAM (S. Africa) MYLAN (US) TEVA PHARMA (Israel)
The market scaled new life-time highs this week but it was the bears who took control. The benchmark indices, Sensex and Nifty ended mostly flat for the week but the momentum was in favour of the bears.
For the quarter ended June 2020, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 54.2% YoY). Sales on the other hand came in at Rs 11 bn (up 6.5% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, ABBOTT INDIA has posted a net profit of Rs 1 bn (down 2.0% YoY). Sales on the other hand came in at Rs 10 bn (up 6.1% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.
For the quarter ended December 2019, ABBOTT INDIA has posted a net profit of Rs 2 bn (up 59.5% YoY). Sales on the other hand came in at Rs 11 bn (up 13.8% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.
For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.
More Views on NewsWere you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...
In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.
Our ace stock picker is ready to capitalise on a big growth opportunity.
The pandemic failed to thwart Richa's investing success formula for 2020.
More